Specialist Supplements COL-Clear B Internal Cleanse Support 100 Capsules

Product Information

UK based test Laboratories have completed the latest Gold Standard COVID-19 testing in October 2020, in which our product achieved Log4, resulting in a 99.99% virucidal kill. CONCORD, Mass.--( BUSINESS WIRE)-- ClearB Therapeutics, Inc., now a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients with chronic hepatitis B (CHB) infection, announced that the first patient has been dosed in the Phase 1b clinical study evaluating the therapeutic vaccine CLB-3000 ( ACTRN1263000841673). Satisfactory review of safety data for this patient supported opening enrollment for the remainder of the cohort. In addition, ClearB Therapeutics announced the acceptance of an abstract including new preclinical data for a humanized monoclonal antibody as serotherapy for the treatment of CHB for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2023, taking place in Boston, MA November 10 – 14, 2023. In NA-treated group (n=4), a numerically greater average [SD] reduction of -2.51 [1.57] log 10 IU/ml vs. placebo -0.01 [0.04], n=2, p=0.45 was observed. Three of these patients had reductions ≥3.0 log 10 IU/mL by Day 29. One additional patient discontinued at day 4 and was not included in the analysis.

There are other types of data that are related to your behavior online. These other types of data can be deleted separately: Abstract title: A humanized monoclonal antibody 4G2 exhibits anti-viral activity in a mouse model of persistent hepatitis B virus (HBV) infection

In addition to the full study results for the B-Clear trial, GSK will share updates on its specialty and vaccines pipeline at the AASLD meeting in Washington DC, including: GSK3228836 (previously known as ‘ISIS 505358 or IONIS-HBV RX’) was discovered by and jointly developed with Ionis Pharmaceuticals. GSK3228836 is one of the ASO HBV programme assets in-licensed by GSK from Ionis Pharmaceuticals in August 2019. GSK is now fully responsible for all development, regulatory and commercialisation activities and costs. About GSK There were no safety signals to preclude further development. AEs leading to treatment discontinuation occurred in 17 participants overall, with 0–4% frequency in participants on-NA, and 0–7% frequency in participants not-on-NA. Serious AEs (SAEs) were reported in 6 (3%) participants on-NA and 11 (5%) participants not-on-NA; 1 SAE in the on-NA and 3 in the not-on-NA population were considered related to treatment.

Professor Man-Fung Yuen, Principal Investigator and Chief of Division of Gastroenterology and Hepatology, Queen Mary Hospital, The University of Hong Kong, said: “Chronic hepatitis B affects millions of people worldwide and is notoriously difficult to treat. The promising data from the B-Clear study offer the potential for a chance of functional cure for the millions for people who are chronically infected with the virus, particularly for those with low baseline HBsAg levels.” GSK today announced that GSK’836 (GSK3228836), an investigational antisense oligonucleotide, showed marked reductions in hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA compared with placebo after four weeks treatment in people with chronic hepatitis B on stable nucleoside or nucleotide analogue (NA) therapy and in patients who were NA-naïve.He worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Virus Laboratory) from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL. He subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998. Phase II trials ongoing to explore potential sequential treatment options with the aim of increasing functional cure rate Phase 2a data to be presented at The Digital International Liver Congress suggests potential of investigational drug (GSK3228836) to suppress hepatitis B virus after four weeks of treatment. Professor Locarnini is a past director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D for the Western Pacific Region (WPRO). His current major research interests include viral hepatitis, hepatitis vaccines and antiviral chemotherapy with an emphasis on the basic virology of the various agents of hepatitis, the molecular pathogenesis of hepatitis, as well as prevention and public health control measures.